Deal Snapshot: Gilead adds to its pipeline of multispecific antibodies for cancer, while Merus gets a first partner for its trispecific platform.

Anthony DeBoer, head of business development at Synaffix, joined the company in 2014 and has helped develop a platform technology business model in the antibody drug conjugate space, where Synaffix has become one of the leading technology providers enabling best-in-class therapeutic candidates.

The second quarter has already seen the approval of Gamida Cell’s cell therapy Omisirge, and with the help of Biomedtracker, Scrip highlights 10 of the more interesting new drug approvals due in the next three months.

The antibody-drug conjugate field is beginning to reach its full potential and big pharma’s attention has been caught.